Cargando…

Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma

BACKGROUND: Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/inte...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Meng-Xin, Liu, Wei-Ren, Wang, Han, Zhou, Yu-Fu, Jin, Lei, Jiang, Xi-Fei, Tao, Chen-Yang, Tang, Zheng, Zhou, Pei-Yun, Fang, Yuan, Qu, Wei-Feng, Ding, Zhen-Bin, Peng, Yuan-Fei, Dai, Zhi, Qiu, Shuang-Jian, Zhou, Jian, Lau, Wan Yee, Fan, Jia, Shi, Ying-Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549297/
https://www.ncbi.nlm.nih.gov/pubmed/31164128
http://dx.doi.org/10.1186/s12916-019-1341-6
_version_ 1783423975879081984
author Tian, Meng-Xin
Liu, Wei-Ren
Wang, Han
Zhou, Yu-Fu
Jin, Lei
Jiang, Xi-Fei
Tao, Chen-Yang
Tang, Zheng
Zhou, Pei-Yun
Fang, Yuan
Qu, Wei-Feng
Ding, Zhen-Bin
Peng, Yuan-Fei
Dai, Zhi
Qiu, Shuang-Jian
Zhou, Jian
Lau, Wan Yee
Fan, Jia
Shi, Ying-Hong
author_facet Tian, Meng-Xin
Liu, Wei-Ren
Wang, Han
Zhou, Yu-Fu
Jin, Lei
Jiang, Xi-Fei
Tao, Chen-Yang
Tang, Zheng
Zhou, Pei-Yun
Fang, Yuan
Qu, Wei-Feng
Ding, Zhen-Bin
Peng, Yuan-Fei
Dai, Zhi
Qiu, Shuang-Jian
Zhou, Jian
Lau, Wan Yee
Fan, Jia
Shi, Ying-Hong
author_sort Tian, Meng-Xin
collection PubMed
description BACKGROUND: Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. METHODS: Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. RESULTS: By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3(intratumoral (T)), CD27(T), CD68(peritumoral (P)), CD103(T), and PD1(T). Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548–0.597; validation cohort, 0.519–0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. CONCLUSIONS: Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1341-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6549297
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65492972019-06-06 Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma Tian, Meng-Xin Liu, Wei-Ren Wang, Han Zhou, Yu-Fu Jin, Lei Jiang, Xi-Fei Tao, Chen-Yang Tang, Zheng Zhou, Pei-Yun Fang, Yuan Qu, Wei-Feng Ding, Zhen-Bin Peng, Yuan-Fei Dai, Zhi Qiu, Shuang-Jian Zhou, Jian Lau, Wan Yee Fan, Jia Shi, Ying-Hong BMC Med Research Article BACKGROUND: Intratumoral immune infiltrates have manifested a robust prognostic signature in patients with hepatocellular carcinoma (HCC). We hypothesized that a novel tissue-related immune signature (TRIS) could improve the prediction of postoperative survival for patients diagnosed with early/intermediate HCC. METHODS: Twenty-eight immune features were immunohistochemically examined on 352 HCC specimens. The LASSO Cox regression model was used to construct a five-feature-based TRIS. The univariate and multivariate Cox analyses were performed. Based on independent predictors, the immune-clinical prognostic index (ICPI) was established. Performance assessment was measured with C-index and compared with seven traditional staging systems. The independent validation cohort (n = 393) was included to validate the model. RESULTS: By using the LASSO method, the TRIS were constructed on the basis of five immune features, CD3(intratumoral (T)), CD27(T), CD68(peritumoral (P)), CD103(T), and PD1(T). Multivariate Cox analysis showed that the TRIS was an independent prognostic predictor. In the training cohort, γ-glutamyl transferase, tumor diameter, tumor differentiation, and TRIS were incorporated into the ICPI. The ICPI presented satisfactory discrimination ability, with C-index values of 0.691 and 0.686 in the training and validation cohorts, respectively. Compared with seven conventional staging systems (C-index, training cohort, 0.548–0.597; validation cohort, 0.519–0.610), the ICPI exhibited better performance for early/intermediate-stage HCCs. Further, the patients were categorized into three subgroups with X-tile software, and the stratified ICPI presented a superior corrected Akaike information criterion and homogeneity in both cohorts. CONCLUSIONS: Our ICPI was a useful and reliable prognostic tool which may offer good individualized prediction capability for HCC patients with early/intermediate stage. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12916-019-1341-6) contains supplementary material, which is available to authorized users. BioMed Central 2019-06-05 /pmc/articles/PMC6549297/ /pubmed/31164128 http://dx.doi.org/10.1186/s12916-019-1341-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Tian, Meng-Xin
Liu, Wei-Ren
Wang, Han
Zhou, Yu-Fu
Jin, Lei
Jiang, Xi-Fei
Tao, Chen-Yang
Tang, Zheng
Zhou, Pei-Yun
Fang, Yuan
Qu, Wei-Feng
Ding, Zhen-Bin
Peng, Yuan-Fei
Dai, Zhi
Qiu, Shuang-Jian
Zhou, Jian
Lau, Wan Yee
Fan, Jia
Shi, Ying-Hong
Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
title Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
title_full Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
title_fullStr Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
title_full_unstemmed Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
title_short Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
title_sort tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6549297/
https://www.ncbi.nlm.nih.gov/pubmed/31164128
http://dx.doi.org/10.1186/s12916-019-1341-6
work_keys_str_mv AT tianmengxin tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT liuweiren tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT wanghan tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT zhouyufu tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT jinlei tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT jiangxifei tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT taochenyang tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT tangzheng tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT zhoupeiyun tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT fangyuan tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT quweifeng tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT dingzhenbin tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT pengyuanfei tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT daizhi tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT qiushuangjian tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT zhoujian tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT lauwanyee tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT fanjia tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma
AT shiyinghong tissueinfiltratinglymphocytessignaturepredictssurvivalinpatientswithearlyintermediatestagehepatocellularcarcinoma